fentin hydroxide : An organotin compound that is triphenylstannane in which the hydrogen attached to tin is replaced by a hydroxy group. A fungicide used to control a variety of infections including blight on potatoes, leaf spot on sugar beet and alternaria blight on carrots. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6327657 |
| CHEBI ID | 30473 |
| SCHEMBL ID | 70052 |
| MeSH ID | M0050848 |
| Synonym |
|---|
| dtxsid1021409 , |
| sn(oh)ph3 |
| fentin |
| CHEBI:30473 , |
| triphenylstannylium hydroxide |
| [sn(oh)ph3] |
| K19 , |
| fintin hydroxid |
| fintine hydroxyde |
| du-ter w-50 |
| triphenyltin hydroxide |
| triphenyltin oxide |
| trifenyl-tinhydroxyde |
| dowco 186 |
| triphenyl-zinnhydroxid |
| du-ter |
| triphenylstannanol |
| suzu h |
| idrossido di stagno trifenile |
| vancide ks |
| ent 28009 |
| tenhide |
| fintin idrossido |
| nci-c00260 |
| fenolovo |
| wln: q-sn-r&r&r |
| k 19 |
| nsc113243 |
| hydroxytriphenylstannane |
| hydroxytriphenyltin |
| stannol, triphenyl- |
| fintin hydroxyde |
| hydroxyde de triphenyl-etain |
| duter |
| duter extra |
| fentin hydroxide |
| stannane, hydroxytriphenyl- |
| 76-87-9 |
| erithane |
| tpth |
| tin, hydroxytriphenyl- |
| tptoh |
| haitin wp 60 (fentin hydroxide 60%) |
| hsdb 1784 |
| du-ter fungicide |
| triphenylstannium hydroxide |
| caswell no. 896e |
| super tin 4l gardian flowable fungicide |
| du-ter fungicide wettable powder |
| oms 1017 |
| ida, imc flo-tin 4l |
| epa pesticide chemical code 083601 |
| einecs 200-990-6 |
| haitin |
| trifenyl-tinhydroxyde [dutch] |
| brestan h 47.5 wp fungicide |
| haitin wp 20 (fentin hydroxide 20%) |
| du-ter pb-47 fungicide |
| idrossido di stagno trifenile [italian] |
| k 19 (van) |
| flo-tin 4l |
| hydroxyde de triphenyl-etain [french] |
| ccris 612 |
| fintin hydroxyde [dutch] |
| phenostat-h |
| tpth technical |
| fintin hydroxid [german] |
| triphenyl-zinnhydroxid [german] |
| sunitron h |
| brn 4139186 |
| vito spot fungicide |
| triphenyltin(iv) hydroxide |
| wesley technical triphenyltin hydroxide |
| fintine hydroxide [french] |
| trifenylstanniumhydroxid [czech] |
| ai3-28009 |
| fintin idrossido [italian] |
| flo tin 4l |
| du-tur flowable-30 |
| fintine hydroxyde [french] |
| fentin hydroxide [bsi] |
| triple tin 4l |
| nsc 113243 |
| NCGC00163909-02 |
| NCGC00163909-01 |
| NCGC00163909-03 |
| NCGC00163909-04 |
| C18729 |
| tox21_300754 |
| dtxcid501409 |
| cas-76-87-9 |
| NCGC00254659-01 |
| AKOS015960675 |
| trifenylstanniumhydroxid |
| fintine hydroxide |
| unii-kkl46v5313 |
| SCHEMBL70052 |
| super-tin |
| farmatin |
| ashlade flotin |
| mfcd00013928 |
| fentin hydroxide, pestanal(r), analytical standard |
| fentin-hydroxide |
| Q7843285 |
| triphenylstannanylium;hydroxide |
| ?fentin hydroxide |
Triphenyltin hydroxide (TPTH) is a widely used pesticide that is highly toxic to a variety of organisms including humans. It is a potential contender for the environmental pollutant.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Triphenyltin hydroxide (TPTH) is a widely used pesticide that is highly toxic to a variety of organisms including humans and a potential contender for the environmental pollutant. " | ( In vitro evaluation of the cytotoxic and bactericidal mechanism of the commonly used pesticide triphenyltin hydroxide. Mahanty, S; Raghav, D; Rathinasamy, K, 2017) | 2.12 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The acute oral LD50 in Sprague-Dawley rats was determined to be 171 mg/kg (100-295) for males and 268 mg/kg (205-344) for females." | ( Acute and subacute toxicology and safety evaluation of triphenyl tin hydroxide (Vancide KS). Davis, ER; Marks, MJ; Shanor, SP; Winek, CL, 1978) | 0.26 |
| "The hypothesis that chemically induced overt maternal toxicity induces a characteristic syndrome of adverse developmental effects in the rat was investigated." | ( Effects of chemically induced maternal toxicity on prenatal development in the rat. Chernoff, N; Miller, DB; Rogers, JM; Rosen, MB; Setzer, RW, 1990) | 0.28 |
| " Intraperitoneal administration of TPTA or TPTH, however, resulted in meaningless random increases in MN though these increases might be attributable to toxic effects." | ( Genotoxic effects of triphenyltin acetate and triphenyltin hydroxide on mammalian cells in vitro and in vivo. Chao, JS; Chen, HH; Huang, MC; Liang, SC; Wei, LY, 1999) | 0.56 |
| "5mg/kg body wt/day were toxic to mothers." | ( Developmental toxicity of triphenyltin hydroxide in mice. De-Carvalho, RR; Delgado, IF; Paumgartten, FJ; Sarpa, M, 2007) | 0.64 |
| " Toxic effects of this compound to aquatic life have been reported; however, the biochemical response of fish exposed to different concentrations of TPhT hydroxide (TPhTH) was investigated for the first time in this study." | ( Toxicity of triphenyltin hydroxide to fish. Antes, FG; Baldisserotto, B; Becker, AG; Clasen, B; Dressler, VL; Flores, EM; Lópes, T; Loro, VL; Parodi, TV, 2013) | 0.77 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " It exhibited an antifertility action, especially in Sprague-Dawley rats dosed on day 1 through day 7 of timed-pregnancy." | ( Acute and subacute toxicology and safety evaluation of triphenyl tin hydroxide (Vancide KS). Davis, ER; Marks, MJ; Shanor, SP; Winek, CL, 1978) | 0.26 |
| " Pregnant animals (Sprague-Dawley strain) were dosed by oral gavage with one of a series of compounds on days 6-15 of gestation." | ( Effects of chemically induced maternal toxicity on prenatal development in the rat. Chernoff, N; Miller, DB; Rogers, JM; Rosen, MB; Setzer, RW, 1990) | 0.28 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 5.6381 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 2.5119 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 1.5849 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 5.8500 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.0959 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 16.6684 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924; AID1347035 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 16.6684 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924; AID1347035 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.0536 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 5.2587 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 0.2434 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 1.1160 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 0.3576 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 17.6876 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 17.1126 | 0.0002 | 14.3764 | 60.0339 | AID588533; AID720691; AID720692; AID720719 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 0.1674 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 1.0020 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 0.3819 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 6.4811 | 0.3758 | 27.4851 | 61.6524 | AID588527; AID743217; AID743220; AID743239 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 3.2032 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 8.9033 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 5.2842 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535; AID743212; AID743215; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 10.7700 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743094; AID743140; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 0.1643 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223 |
| caspase-3 | Homo sapiens (human) | Potency | 0.2434 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.1723 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 7.2128 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1259385; AID1259395 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 31.1447 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 7.8422 | 0.1549 | 17.8702 | 43.6557 | AID1346877; AID1346891 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 2.0929 | 19.7391 | 45.9784 | 64.9432 | AID1159509; AID1159518 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 10.7675 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 0.5557 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 0.1369 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 3.1623 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 183.8083 | 0.0100 | 39.5371 | 1,122.0200 | AID1479; AID588545; AID588547 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 0.1369 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 0.0477 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 6.8931 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 4.4668 | 24.8329 | 44.6684 | AID651749 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 1.3135 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 2.5146 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 1.2197 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 6.9573 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743; AID720552 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 1.2197 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 0.0628 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 0.0486 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (39.29) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 5 (17.86) | 29.6817 |
| 2010's | 9 (32.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.33) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (3.45%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 28 (96.55%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||